Drug · Small Molecule

Carboplatin

CI-DRUG-00000139Explore in graph →NCIt C1282 CHEMBL1351 CIViC Approved

Regulatory

Approvals (13)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory13 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02320371) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 11, 2015	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION (DIN 02366053) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 28, 2020	Jun 10, 2013	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CARBOPLATIN INJECTION BP (DIN 02126680) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	671	337	543	2,361	13	CA, US	Dec 31, 1994	1988-03
Malignant Ovarian Neoplasm	Approved	Phase 4	52	26	61	282	2	US	Aug 8, 2025	1989-04
Malignant Lung Neoplasm	Phase4	Phase 4	241	118	220	822	0	—	—	1994-12
Malignant Breast Neoplasm	Phase4	Phase 4	88	40	47	267	0

Curated evidence

Clinical evidence (38)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–38 of 38 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCND1 Amplification1
Carboplatin + Paclitaxel

Clinical trials

Trials with this intervention (2,385)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 2,351–2,385 of 2,385 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00165139	Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas	completed	Phase 2	20	Dana-Farber Cancer InstituteOTHER	1	Nov 2, 2009	clinicaltrials
NCT00363415	Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer	completed

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: BG3F62OND5
Aliases: 1,1-cyclobutanedicarboxylic Acid Platinum Complex, Blastocarb, Carboplat, Carboplatin, Carboplatine, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum(II), Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum, Cis-diammine(cyclobutanedicarboxylato)platinum II, Displata, Ercar, JM-8, JM8, KYXATA, Nealorin, Novoplatinum, NSC-201345, NSC-241240, Paraplat, Paraplatin, Paraplatin AQ, PARAPLATIN-AQ, Paraplatine, Platinum, Diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2) … (+3)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (23)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XA02	CARBOPLATIN
DIN (Health Canada)	00680060

High2
Carboplatin + Dostarlimab + PaclitaxelCombination	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12341 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 36972026 · Mirza et al., 2023 · Open in CIViC	civic
〃	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12343 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 38866180 · Powell et al., 2024 · Open in CIViC	civic

PTEN Loss2
Buparlisib + Carboplatin + PaclitaxelCombination	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID714 All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers. PMID 25672916 · Hyman et al., 2015 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5957 In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC) PMID 28281183 · Smyth et al., 2017 · Open in CIViC	civic

NF1 G629R + NF1 Splice Site (c.205-1G>C)2
Carboplatin + Selumetinib + Trametinib + VincristineSubstitutes	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID12271 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic
〃	Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	2	rejected	EID12359 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic